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It is well established that alterations in energy metabolism are present in most 
neurodegenerative disorders. Some of these alterations are due to mitochondrial 
dysfunctions that occur in parallel to an exacerbated production of reactive oxygen 
species (ROS). From a quantitative viewpoint, mitochondria are thought to be the 
largest contributors to intracellular ROS production in most cell types. Under specific 
circumstances, mitochondria produce excess ROS (mROS) leading cells to undergo 
oxidative stress and apoptotic death. Amongst the different mROS sources, the 
mitochondrial respiratory chain complexes I and III appear to be important. However, 
increasing evidence now suggest the important contribution of certain metabolic 
enzymes of the mitochondrial matrix, such as pyruvate dehydrogenase complex and the 
tricarboxylic acid (TCA) cycle enzyme 2-oxoglutarate dehydrogenase complex 
(KGDHC), or embedded in the inner mitochondrial membrane, such as 
glycerolphosphate dehydrogenase and the flavoprotein-ubiquinone oxidoreductase 
mitochondrial system (Holmström and Finkel, 2014). 
 
KGDHC is one of the key regulatory enzymes of the TCA cycle, and its activity is 
mainly controlled by the cellular redox state, by ATP and by the KGDHC product, 
succinyl-CoA. In brain tissue, KGDHC is also involved in neurotransmitter 
biosynthesis. Thus, α-ketoglutarate (α-KG) is the precursor of glutamate and glutamine 
biosynthesis, in neurons and astrocytes, respectively, and of GABA synthesis in 
GABAergic neurons. Therefore, three major tasks of the brain cells, namely 
neurotransmitter biosynthesis, energy conservation, and redox homeostasis, are 
potentially linked to mROS metabolism by the KGDHC activity. However, the 
significance, mechanism and regulation of KGDHC-mediated ROS production have 
remained elusive. 
 
Chen and colleagues (2016) now show that transient up- or down-modulation of 
KGDHC activity can play a protective role against exogenously excess ROS. In 
essence, they propose that perturbation in metabolism caused by transient reductions in 
KGDHC would activate cellular antioxidant systems to overcome a prospective increase 
in ROS. Moreover, they also show that decreasing KGDHC activity –either acutely in 
vivo, or chronically in vitro- triggers KGDHC-mediated excess ROS. Thus, increases in 
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the mitochondrial NADH/NAD
+
 ratio switch KGDHC to a less active ROS-production 
mode that is self-protected against excess ROS. This is performed by KGDHC 
glutathionylation (McLain et al. 2013), a process that occurs during increased oxidized 
glutathione (GSSG) concentrations caused by excess ROS. Thus, KGDHC activity can 
plays a key role in mROS homeostasis. 
 
In previous reports, the authors had shown that specific inhibition of KGDHC in intact 
cerebellar granule neurons increased α-KG, increased transamination of α-KG with 
valine, leucine and GABA (Santos, et al. 2006), increased GABA shunt and produced 
changes in glycolysis (Shi, et al. 2009, Nilsen, et al. 2011). Interestingly, glycolysis 
activation in neurons triggers glutathione oxidation to GSSG due to a shift of the 
pentose phosphate pathway (PPP) (Herrero-Mendez et al. 2009; Rodriguez-Rodriguez 
et al. 2012). Whether such an increase in glycolysis is consequence of KGDHC 
inhibition, or is part of an overall increase in glucose metabolism that takes place during 
PPP impairment, may be worth elucidating. Furthermore, it is interesting to note the 
apparent link between KGDHC activity and endoplasmic reticulum Ca
2+
 stores 
observed by Chen et al. (2016), although the underlying mechanism still remains to be 
fully elucidated. Thus, the authors previously described the accumulation of bombesin-
released Ca
2+
 stores (BRCS) by exogenous ROS, which resembles those observed in 
neurodegenerative disorders. Now, the authors show that the chronic inhibition of 
KGDHC in vivo potentiates the effect of the free-radical donor tert-butylhydroperoxide 
(t-BHP) on BRCS in primary neurons, an effect that is rescued by the over-expression 
of the KGDHC subunit, 2-oxoglutarate dehydrogenase. These results clearly show that 
the response of BRCS to externally added ROS is modulated by KGDHC activity. 
However, whether the observed effect on BRCS is an indirect consequence of KGDHC 
activity-mediated ROS, or its takes place by different, yet unknown mechanism(s), 
remains to be investigated. 
 
Taken together, the results presented by Chen et al. (2016) adds novel functions to the 
long list of metabolic tasks of KGDHC, thus raising the possibility to consider the 
pharmacological control of KGDHC activity as a therapeutic strategy against the 
bioenergetics deficiency of neurodegenerative disorders. 
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Figure 1 legend 
 
Outline diagram of the main conclusion by Chen et al. (2016). Tuning KGDHC activity 
progressively controls mROS production with different cellular outcomes. Long-term 
KGDHC inhibition releases harmful excess mROS, whereas short-term inhibition or 
mild activation of KGDHC either slightly increases or decreases, respectively, 
neuroprotective mROS. 
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